ライフサイエンスコーパス: thromboses

1 ther conditions associated with pathological thromboses.

2 rovascular aneurysms, or arterial and venous thromboses.

3 the cost of an increased risk of late stent thromboses.

4 atment with heparin resulting in paradoxical thromboses.

5 ents with rapidly progressive multiple organ thromboses.

6 s of heart disease are at increased risk for thromboses.

7 ability to inhibit both venous and arterial thromboses.

8 ved to influence the development of arterial thromboses.

9 ology of rejection characterized by vascular thromboses.

10 elet reactivity with a resulting increase in thromboses.

11 urred in 8 pts (23.5%): 4 bleeding, 3 portal thromboses (1 complete, 2 partial), and 1 sepsis.

12 the fish oil group, there were half as many thromboses (1.71 vs 3.41 per 1000 access-days; IRR, 0.50

13 perior in the prevention of catheter-related thromboses (13 [3%] vs 34 [7%]; 0.38, 0.20-0.71, p=0.002

14 tenoses, one dissection), 185 in the EIA (17 thromboses, 167 stenoses, one dissection), one in the co

15 ases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial and venous thrombosis, 2

16 did not reduce the rate of catheter-related thromboses (24 [6%] vs 24 [6%]; relative risk 0.99, 95%

17 FvQ/Q mice formed occlusive thromboses 27+/-3 minutes (n=7) after the onset of injur

18 ke (2.44 [1.04-5.75], p = 0.04) and arterial thromboses (3.49 [0.97-12.54], p = 0.05).

19 was compromised in 20 cases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial a

20 pulmonary embolisms (42.2%), and deep venous thromboses (34.5%).

21 A clinically significant HAC (4 thromboses, 35 HACs requiring IVI) was found in 2.9% (n

22 imultaneous patients had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

23 intimal dissections, 11 pseudoaneurysms, 17 thromboses, 4 carotid cavernous fistulas, and 1 transect

24 A risk-benefit analysis found 3 fewer stent thromboses (95% CI: 2 to 5) and 6 fewer MIs (95% CI: 2 t

25 ts to proximal pulmonary arterial aneurysms, thromboses and calcification; to truncal valve stenosis

26 ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary emboli

27 r mediated pathways leading to microvascular thromboses and endothelial activation appear to play an

28 A combined endpoint of thromboses and major bleeding showed no difference betwe

29 ies are at risk for major abdominal vascular thromboses and organ infarction.

30 symptoms to life-threatening events such as thromboses and strokes.

31 7%) were non-catheter-associated deep venous thromboses, and 9 (0.6%) were pulmonary emboli.

32 ythropoiesis and granulopoiesis, more venous thromboses, and a higher rate of polycythaemic transform

33 Thromboses are a serious complication in patients with s

34 but catheter occlusions and catheter-related thromboses are common complications that can result from

35 treatment of central venus catheter-related thromboses are critical in the treatment of patients req

36 Thromboses are detected frequently around the time of on

37 Other thromboses are found on non-ruptured but inflamed plaque

38 Catheter-related thromboses are usually diagnosed by Doppler ultrasonogra

39 Gender differences in vascular thromboses are well known, and there is evidence that pl

40 thrombocytopenic purpura and other arterial thromboses associated with compromised VWF proteolysis.

41 ring revision of TIPS with one to five prior thromboses at 1 day to 1 year after initial TIPS formati

42 nted with Fv+/+ bone marrow formed occlusive thromboses at 35+/-5 minutes (n=7, P<0.05 compared with

43 AMTS-13 activity, and VWF-rich microvascular thromboses at autopsy.

44 Five patients (33%) developed venous thromboses at the central catheter tip.

45 Vascular thromboses, bowel perforation, septicemia, and retranspl

46 prevent CVC infections and catheter-related thromboses, but confirmatory studies and cost-effectiven

47 Catheter-related thromboses can lead to catheter infection, pulmonary emb

48 inding in human VCA, consisting of capillary thromboses (CT) in the upper dermis.

49 An uncomplicated deep vein thromboses developed in one patient with a history of re

50 Thromboses developed in six of 240 flaps (2.5%): 4 were

51 mboli (PE) in cancer patients with deep vein thromboses (DVT) was reviewed to identify indications, p

52 The primary outcome was deep vein thromboses (DVTs) averted.

53 mia should undergo ultrasonography to detect thromboses even if the physical examination is normal.

54 h late portal vein or vena caval stenoses or thromboses from a cohort of 524 grafts with survival gre

55 Two patients with symptoms of in situ thromboses had a higher percentage of adherent cells com

56 ocytopenia (HIT) develop clinically apparent thromboses (HITT) remains uncertain.

57 among patients without thrombosis; among 40 thromboses in 40 patients who did not undergo transplant

58 and comparable between groups, with no stent thromboses in any group at 6 months.

59 rent CAPS characterized by multiple arterial thromboses in large and small vessels despite maximal an

60 ion in symptomatic catheter-related or other thromboses in patients with cancer and therefore we shou

61 population there were 22 (16.5%) episodes of thromboses in the fondaparinux group and 13 (21.4%) in t

62 om 6 months to 3 years there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% co

63 e confirmed in 66 patients; an additional 36 thromboses in unique devices were suspected.

64 Risk factors for catheter-related thromboses include previous catheter infections, malposi

65 Prevention of catheter-related thromboses includes proper positioning of the CVC and pr

66 ), pulmonary embolism (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), an

67 Twenty-two (52%) had major vascular thromboses, including those in the inferior vena cava (n

68 Thromboses limited to infrapopliteal leg deep veins (iso

69 ocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other

70 No deaths, malignancies, or thromboses occurred during the trial.

71 Stent thromboses occurred in 1 patient assigned to placebo <24

72 Two maternal valve thromboses occurred.

73 win sister, who was diagnosed with extensive thromboses of the inferior vena cava, portal vein, and h

74 vents per 100 patient-years) compared with 2 thromboses on eculizumab (0.8 events per 100 patient-yea

75 These studies demonstrate markedly increased thromboses on stents with blood isolated from HPA Tg mic

76 fold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute,

77 -risk groups such as those with prior venous thromboses or coexistent defects of anticoagulation and

78 32-65 years; mean age, 42 years), abdominal thromboses or ischemic events were detected at CT.

79 Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and conf

80 factors [HRF] (multiple arteriovenous access thromboses, prior deep vein thrombosis, prior allograft

81 s risk factors in patients with a history of thromboses; red cell binding sites on endothelial cells

82 2 combined arterial and venous thrombosis, 2 thromboses secondary to allograft pancreatitis, and 3 ca

83 tiple vessel-related complications including thromboses, stenoses, occlusions, and aneurysms.

84 tiple vessel-related complications including thromboses, stenoses, occlusions, and aneurysms.

85 There were no instances of graft vascular thromboses/stenoses/leaks (0%).

86 view of CT scans revealed more grade 1 and 2 thromboses than were initially reported.

87 atient with a history of recurrent deep vein thromboses that had no adverse effect on her outcome.

88 ght heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated.

89 hepatic artery stenoses, six hepatic artery thromboses, two hepatic artery pseudoaneurysms, two sple

90 Stent thromboses were also assessed.

91 A total of 72 pump thromboses were confirmed in 66 patients; an additional

92 Main sites of thromboses were deep veins of the extremities (10 of 23;

93 uary 2008 and September 2013, 26 (0.61%) THV thromboses were reported out of 4266 patients undergoing

94 No late stent thromboses were seen in any treated group despite clopid

95 passing treatment of any unknown concomitant thromboses with only low risk for hemorrhage.

96 symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen.

97 There were no deep vein thromboses, with 1 superfificial venous thrombosis in ea